Filing Overview
Indaptus Therapeutics, Inc. filed this Form 8-K on August 16, 2021, reporting under Item 9.01 following its business combination with Decoy Biosystems, Inc. The transaction closed on August 3, 2021, with Decoy surviving as a wholly owned subsidiary. The filing includes Decoy’s unaudited interim financial statements and unaudited pro forma condensed combined financial information.
Business Context and Reporting Period
- Decoy’s interim financial statements cover June 30, 2021 and December 31, 2020, and the six months ended June 30, 2021.
- The pro forma balance sheet is presented as of June 30, 2021, assuming the merger occurred on that date.
- The pro forma statements of operations cover the six months ended June 30, 2021, assuming the merger occurred on January 1, 2021.
Financial Metrics
The filing text provided does not include the numerical financial statements from Exhibits 99.1 and 99.2. Accordingly, revenue, net income or loss, operating expenses, cash flow, margins, debt, cash, liquidity, and other financial metrics cannot be determined from the provided text.
Material Changes Versus Prior Comparable Period
The principal reported change is the completion of the business combination, under which Decoy became a wholly owned subsidiary of Indaptus. The filing does not provide sufficient financial statement detail to quantify changes from the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- No management guidance or operating outlook is provided in the filing text.
- No new risks, contingencies, commitments, or unusual operating items are described in the provided text.
- The merger and related pro forma presentation are the material corporate events disclosed.
Investor Verification Checklist
- Review Exhibit 99.1 for Decoy’s cash position, accumulated deficit, operating expenses, net loss, and cash used in operations.
- Review Exhibit 99.2 for the combined company’s pro forma assets, liabilities, equity, results of operations, and transaction adjustments.
- Confirm the accounting treatment, ownership structure, and capitalization effects of the August 3, 2021 merger.
- Assess the combined company’s liquidity and financing requirements using the complete financial statements and subsequent SEC filings.